Kanelina Bimpa
Research Subjects
Research Interests
Kanelina Bimpa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Angelos Sioutas
Private practice Thessaloniki Greece
1 shared publication- Apostolos C. Ziogas
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Thessaly, Mezourlo, 41100 Larissa, Greece
1 shared publication - Elias Tsakos
Embryoclinic, IVF Unit
1 shared publication - Emmanouil M. Xydias
EmbryoClinic IVF, 6 Andrianoupoleos 55133, Thessaloniki, Greece; Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, AUTH Campus 54124, Thessaloniki, Greece
1 shared publication - Georgios Tampakoudis
Maternal‐Fetal Medicine and Obstetrics Saint Luke's Hospital Thessaloniki Greece
1 shared publication Katerina Zarampouka
Pathology Department Istodierevnitiki SA Thessaloniki Greece
1 shared publication
Latest Publications
- Open Access
- 19 September 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (9) , e6322
Uterine malignant leiomyosarcoma associated with high levels of serum beta‐human chorionic gonadotropin: A case report
We present the case of a 54‐year‐old woman diagnosed with uterine leiomyosarcoma that produced beta‐human chorionic gonadotropin (β‐hCG), evident by both serum and immunohistologic examination. Based on this and similar cases from the available literature, β‐hCG‐producing sarcomas tend to have poorer prognosis, indicating that β‐hCG could potentially be used as a marker of disease status and response to the therapy; however, this association is inconsistent and should be further investigated.
- 19 September 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (9) , e6322
Open AccessUterine malignant leiomyosarcoma associated with high levels of serum beta‐human chorionic gonadotropin: A case report
We present the case of a 54‐year‐old woman diagnosed with uterine leiomyosarcoma that produced beta‐human chorionic gonadotropin (β‐hCG), evident by both serum and immunohistologic examination. Based on this and similar cases from the available literature, β‐hCG‐producing sarcomas tend to have poorer prognosis, indicating that β‐hCG could potentially be used as a marker of disease status and response to the therapy; however, this association is inconsistent and should be further investigated.